Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Cornberg

Showing results (281-290 of 350) with videos related to

Pageof 35
Sort By:
Journal of Hepatology|November 26, 2020
Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severityLisette A P Krassenburg, Raoel Maan, Alnoor Ramji, et al.
Hepatology Communications|September 29, 2021
Low Serum Cholinesterase Identifies Patients With Worse Outcome and Increased Mortality After TIPSLena Stockhoff, Theresa Muellner-Bucsics, Antoaneta A Markova, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|April 1, 2021
The impact of hepatitis B surface antigen on natural killer cells in patients with chronic hepatitis B virus infectionYanqin Du, Olympia E Anastasiou, Benedikt Strunz, et al.
Signal Transduction and Targeted Therapy|December 11, 2021
Endothelial dysfunction contributes to severe COVID-19 in combination with dysregulated lymphocyte responses and cytokine networksLouisa Ruhl, Isabell Pink, Jenny F Kühne, et al.
Hepatology Communications|January 13, 2021
Pilot Study Using Machine Learning to Identify Immune Profiles for the Prediction of Early Virological Relapse After Stopping Nucleos(t)ide Analogues in HBeAg-Negative CHBMaximilian Wübbolding, Juan Carlos Lopez Alfonso, Chun-Yen Lin, et al.
Gut|October 24, 2020
TOX defines the degree of CD8+ T cell dysfunction in distinct phases of chronic HBV infectionKathrin Heim, Benedikt Binder, Sagar, et al.
Plos One|June 10, 2015
Treatment Extension of Pegylated Interferon Alpha and Ribavirin Does Not Improve SVR in Patients with Genotypes 2/3 without Rapid Virological Response (OPTEX Trial): A Prospective, Randomized, Two-Arm, Multicentre Phase IV Clinical TrialBenjamin Heidrich, Hans-Jörg Cordes, Hartwig Klinker, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 13, 2016
Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and CirrhosisRaoel Maan, Marjolein van Tilborg, Katja Deterding, et al.
Journal of Hepatology|April 16, 2019
Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacyCihan Yurdaydin, Zaigham Abbas, Maria Buti, et al.
United European Gastroenterology Journal|November 29, 2025
Ten-Year Follow-Up After 96 Weeks Treatment With Peginterferon Plus Tenofovir in Hepatitis D (HIDIT-II): Improved Clinical Outcome After Combination TherapyCihan Yurdaydin, Julia Kahlhöfer, Florin Alexandru Caruntu, et al.
Pageof 35

Showing results (281-290 of 350) with videos related to

Sort By:
Pageof 35
Journal of Hepatology|November 26, 2020
Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severityLisette A P Krassenburg, Raoel Maan, Alnoor Ramji, et al.
Hepatology Communications|September 29, 2021
Low Serum Cholinesterase Identifies Patients With Worse Outcome and Increased Mortality After TIPSLena Stockhoff, Theresa Muellner-Bucsics, Antoaneta A Markova, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|April 1, 2021
The impact of hepatitis B surface antigen on natural killer cells in patients with chronic hepatitis B virus infectionYanqin Du, Olympia E Anastasiou, Benedikt Strunz, et al.
Signal Transduction and Targeted Therapy|December 11, 2021
Endothelial dysfunction contributes to severe COVID-19 in combination with dysregulated lymphocyte responses and cytokine networksLouisa Ruhl, Isabell Pink, Jenny F Kühne, et al.
Hepatology Communications|January 13, 2021
Pilot Study Using Machine Learning to Identify Immune Profiles for the Prediction of Early Virological Relapse After Stopping Nucleos(t)ide Analogues in HBeAg-Negative CHBMaximilian Wübbolding, Juan Carlos Lopez Alfonso, Chun-Yen Lin, et al.
Gut|October 24, 2020
TOX defines the degree of CD8+ T cell dysfunction in distinct phases of chronic HBV infectionKathrin Heim, Benedikt Binder, Sagar, et al.
Plos One|June 10, 2015
Treatment Extension of Pegylated Interferon Alpha and Ribavirin Does Not Improve SVR in Patients with Genotypes 2/3 without Rapid Virological Response (OPTEX Trial): A Prospective, Randomized, Two-Arm, Multicentre Phase IV Clinical TrialBenjamin Heidrich, Hans-Jörg Cordes, Hartwig Klinker, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 13, 2016
Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and CirrhosisRaoel Maan, Marjolein van Tilborg, Katja Deterding, et al.
Journal of Hepatology|April 16, 2019
Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacyCihan Yurdaydin, Zaigham Abbas, Maria Buti, et al.
United European Gastroenterology Journal|November 29, 2025
Ten-Year Follow-Up After 96 Weeks Treatment With Peginterferon Plus Tenofovir in Hepatitis D (HIDIT-II): Improved Clinical Outcome After Combination TherapyCihan Yurdaydin, Julia Kahlhöfer, Florin Alexandru Caruntu, et al.
Pageof 35